title: VP16 and TBI as conditioning regimen for allogeneic BMT in patients with high risk and relapsed ALL and NHL.
authors.affiliation: UKRV Charlottenburg, Berlin, FRG.
authors.forename: R
authors.initials: R
authors.lastname: Schwerdtfeger
authors.forename: H
authors.initials: H
authors.lastname: Schmid
authors.forename: H
authors.initials: H
authors.lastname: Baurmann
authors.forename: S
authors.initials: S
authors.lastname: Kleiner
authors.forename: T
authors.initials: T
authors.lastname: Zeiler
authors.forename: G
authors.initials: G
authors.lastname: Henze
authors.forename: W
authors.initials: W
authors.lastname: Siegert
mesh_terms: D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation / Q000379:methods* / Q000401:mortality; D002648:Child; D002675:Child, Preschool; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000401:mortality / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology / Q000601:surgery; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000401:mortality / Q000601:surgery*; D012074:Remission Induction; D012086:Reoperation; D012307:Risk Factors; D014916:Whole-Body Irradiation / Q000009:adverse effects
chemical_list: D005047:Etoposide